Odyssey Health, Inc.
ODYYOTCHealthcare · Surgical & Medical Instruments & Apparatus · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 |
| Operating income | −$1.0M | −$2.1M | −$5.3M | −$8.1M | −$15.9M | −$3.8M |
| Net income | −$1.7M | −$842,316 | −$5.9M | −$8.4M | −$16.9M | −$4.3M |
| Total assets | $49,723 | $586,146 | $455,793 | $569,677 | $610,533 | $105,584 |
| Total liabilities | — | — | — | — | $3.4M | $757,063 |
| Equity | −$7.0M | −$5.3M | −$6.2M | −$4.6M | −$2.8M | −$651,478 |
| EPS (diluted) | $-0.02 | $-0.01 | $-0.07 | $-0.09 | $-0.18 | $-0.05 |
| Shares out. | 99.9M | 96.7M | 81.7M | 72.0M | 91.0M | 90.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 25.1%
- Return on assets
- −3504.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.07
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −2806.1%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Oct 30, 2024
- NT 10-Qmissed a reporting deadline ↗Mar 18, 2024
- NT 10-Qmissed a reporting deadline ↗Jun 14, 2021
- NT 10-Kmissed a reporting deadline ↗Oct 29, 2020
- NT 10-Kmissed a reporting deadline ↗Oct 29, 2018
- NT 10-Qmissed a reporting deadline ↗Jun 13, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Lutz Jonathan DPassive (13G)Nov 21, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Odyssey Health, Inc.10% owner | Jun 17, 2025 | Sell | 2,000 | $4.46 |
| Odyssey Health, Inc.10% owner | Jun 13, 2025 | Sell | 5,000 | $4.27 |
| Gandolfo John P | Jan 10, 2024 | Grant | 1.5M | $0.09 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 39 | 1.0 | -99.8% |
| Apr 30, 2026 | 19,015 | 1.0 | -40.7% |
| Apr 15, 2026 | 32,083 | 1.0 | -18.1% |
| Mar 31, 2026 | 39,178 | 1.0 | +6.5% |
| Mar 13, 2026 | 36,804 | 1.0 | +80.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligationMay 26, 2026
- Entered a material agreementMay 11, 2026
- Entered a material agreement · Other material eventApr 24, 2026
- Entered a material agreement · New financial obligationFeb 3, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventNov 19, 2025
- Entered a material agreement · Other material eventOct 17, 2025
- Entered a material agreement · New financial obligationOct 10, 2025
- Entered a material agreement · New financial obligationOct 8, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KAMENDMENT #1 TO FORM 8-KMay 26, 2026
- 8-KFORM 8-KMay 11, 2026
- 8-KCURRENT REPORTApr 24, 2026
- 10-QFORM 10-Q FOR JAN 2026Mar 12, 2026
- 8-KCURRENT REPORTFeb 3, 2026
- EFFECTDec 30, 2025
- 424B3FORM 424B3Dec 30, 2025
- S-1REGISTRATION STATEMENTDec 19, 2025
- 10-QFORM 10-Q FOR OCT 2025Dec 11, 2025
- SCHEDULE 13G/ANov 21, 2025
- 8-KCURRENT REPORTNov 19, 2025
- 10-KFORM 10-K FOR JULY 2025Oct 29, 2025
- 8-KCURRENT REPORTOct 17, 2025
- 8-KFORM 8-KOct 10, 2025
- 8-KCURRENT REPORTOct 8, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.